EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Guselkumab in Psoriatic Arthritis: Therapeutic Impact on Axial and Peripheral Involvement—Monocentric Real-World Evidence

Roberta Foti iD, Giorgio Amato, Elisa Visalli, Ylenia Dal Bosco, Francesco De Lucia, Angelo Montana, Giambattista Privitera, Placido Romeo, Fabio Aiello iD, Maria Gabriella Paolì iD, Rosario Foti iD

Journal of Clinical Medicine · 01.05.2025 · 14 (9) · 3151

DOI: 10.3390/jcm14093151 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 01.05.2025. Verfasst von Roberta Foti und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Rheumatology, AOU Policlinico "G. Rodolico" San Marco, 95121 Catania, Italy. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Axial involvement in psoriatic arthritis (axPsA) presents clinical and radiological differences from ankylosing spondylitis (AS), which may influence the therapeutic response. While Guselkumab has demonstrated efficacy in peripheral PsA, its role in axPsA is less well established, particularly in real-world settings.

Objective

To evaluate the positive effects of Guselkumab therapy in patients with psoriatic arthritis (PsA), 58.6% of whom have axial involvement, in a 12-month, single-center, longitudinal, prospective observational cohort study conducted in a real-life setting.

Methods

A cohort of 99 patients with PsA, including 58 with axial involvement (axPsA), was treated with Guselkumab for 12 months. Treatment efficacy was assessed by evaluating the reduction in mBASDAI, ASDAS, DAPSA, VAS Pain, LEI, and HAQ scores. The Friedman test was used to analyze whether the overall changes from baseline to 12 months were statistically significant. Patients with axial involvement were assessed by MRI, with scores measured at baseline (t0), after 6 months (t6), and after 12 months (t12) of therapy. Statistical evaluation was conducted using the Friedman test, followed by pairwise comparisons of values obtained at different follow-up time points using the Wilcoxon signed-rank test. Additionally, the drug’s retention rate was examined using a Kaplan–Meier curve.

Results

After 12 months of therapy, a statistically significant reduction was observed in all clinimetric parameters. Patients with axial involvement were also evaluated by MRI at baseline, after 6 months, and after 12 months of therapy. MRI images showed a reduction in bone marrow edema and a decrease in signal intensity, indicating a significant reduction in inflammation and confirming the drug’s efficacy. Retention rate values demonstrate that Guselkumab is well tolerated and effective in the long term for the majority of patients.

Conclusions

This 12-month real-world study of 99 PsA patients confirms the efficacy of Guselkumab in reducing disease activity in both peripheral and axial forms. The findings align with previous RWE and clinical trials (DISCOVER-1 and -2), supporting its clinical utility in PsA and axPsA, with high treatment retention.

Schlagwörter

Stichwörter der Autor:innen

GuselkumabMRISPARCCankylosing spondylitis (AS)axial psoriatic arthritis (axPsA)biologic drugsinterleukin 23 (IL-23)psoriatic arthritis (PsA)real-world evidencespondyloarthritis (SpA)

Autor:innen und Institutionen

  • Division of Rheumatology, AOU Policlinico "G. Rodolico" San Marco, 95121 Catania, Italy.
  • University of Enna "Kore", 94100 Enna, Italy.
  • Division of Radiology San Marco Hospital, AOU Policlinico "G. Rodolico" San Marco, 95121 Catania, Italy.

ORCID-Profile: Roberta Foti, Fabio Aiello, Maria Gabriella Paolì, Rosario Foti

Zitieren

APA

Foti, R., Amato, G., Visalli, E., Bosco, Y. D., Lucia, F., Montana, A., Privitera, G., Romeo, P., Aiello, F., Paolì, M. G., & Foti, R. (2025). Guselkumab in Psoriatic Arthritis: Therapeutic Impact on Axial and Peripheral Involvement—Monocentric Real-World Evidence. Journal of Clinical Medicine, 14(9), 3151. https://doi.org/10.3390/jcm14093151

Vancouver

Foti R, Amato G, Visalli E, Bosco YD, Lucia F, Montana A, et al. Guselkumab in Psoriatic Arthritis: Therapeutic Impact on Axial and Peripheral Involvement—Monocentric Real-World Evidence. Journal of Clinical Medicine. 2025;14(9):3151. doi:10.3390/jcm14093151

BibTeX
@article{Foti2025,
  author = {Foti, Roberta and Amato, Giorgio and Visalli, Elisa and Bosco, Ylenia Dal and Lucia, Francesco De and Montana, Angelo and Privitera, Giambattista and Romeo, Placido and Aiello, Fabio and Paolì, Maria Gabriella and Foti, Rosario},
  title = {Guselkumab in Psoriatic Arthritis: Therapeutic Impact on Axial and Peripheral Involvement—Monocentric Real-World Evidence},
  journal = {Journal of Clinical Medicine},
  year = {2025},
  volume = {14},
  number = {9},
  pages = {3151},
  doi = {10.3390/jcm14093151}
}
Kostenlos starten →